The effects of diet, of non-steroidal anti-inflammatory drugs, or of their combination on carcinogenesis continue to be a case for controversy. Diets that are high in fat have been linked to increased risk of various tumors. At the same time there is substantial, but not conclusive, evidence that the risk of breast and colon cancer correlates with total fat intake rather than a specific type of fat. On the other hand, non-steroidal anti-inflammatory drugs (NSAIDs) have been studied extensively because they appear to delay or inhibit the development of malignant and pre-malignant lesions. 7,12-Dimethylbenz-(a)-anthracene (DMBA) has been used for a long time to induce carcinogenesis in a number of rat animal models. The present study attempts to identify the effects on DMBA-induced tumor growth (a) of diets rich in fat and (b) of the highly selective COX-2 inhibitor Celecoxib, which has been claimed to offer substantial protection against carcinogenesis.
U. S. Department of Health and Human Services: The Surgeon General's Report on Nutrition and Health, DHHS (PHS) Publ. No. 88-50210. Washington, DC: Dept. of Health and Human Services, Public Health Service, 1988.
2.
National Research Council, Committee on Diet and Health, Food and Nutrition Board, Commission on Life Sciences. Diet and Health: Implications for Reducing Chronic Disease Risk. Washington, DC: National Academy Press, 1989.
HurstingSDThornquistMHendersonMM: Types of dietary fat and the incidence of cancer at five sites. Prev Med1990; 19:242–253.
5.
DaviesGSalterJHillsMMartinL-ASacksNDowsettM. Correlation between Cyclooxygenase-2 Expression and angiogenesis in human breast cancer. Clin Cancer Res2003; 9:2651–56.
6.
BodoMMuziGBellucciC. Comparative in vitro studies on the fibrogenic effects of two samples of silica on epithelial bronchial cells. J Biol Regul Homeost Agents2007; 21:97–104.
7.
WillettWC. Fat, energy and breast cancer. J Nutr1997; 127:921–3.
RogersAE. Diet and breast cancer: Studies in laboratory animals. J Nutr1997; 127:933–5.
10.
SantagostinoASaggiaCMiglioraP. Prospective study on prognostic significance of DNA ploidy and Ki-67 expression in colorectoral cancer. J Biol Regul Homeost Agents2007; 21:13–22.
11.
KritchevskyD. Caloric restriction and experimental mammary carcinogenesis. Breast Cancer Res Treat1997; 46:161–7.
12.
HarvellDMStreckerTEXieBPenningtonKLMcCombRDShullJD. Dietary energy restriction inhibits estrogen-induced mammary, but not pituitary, tumorigenesis in the ACI rat. Carcinogenesis2002; 23:161–9.
13.
ThompsonHJZhuZJiangW. Dietary energy restriction in breast cancer prevention. J Mammary Gland Biol Neoplasia2003; 8:133–42.
14.
ZhuZJiangWThompsonHJ. An experimental paradigm for studying the cellular and molecular mechanisms of cancer inhibition by energy restriction. Mol Carcinog2002; 35:51–6.
15.
HurstingSDKariFW. The anti-carcinogenic effects of dietary energy restriction: Mechanisms and future directions. Mutat Res1999; 443:235–49.
16.
DuBoisRN. New paradigms for cancer prevention. Carcinogenesis2001; 22:691–2.
17.
WaddellWRLoughryRW. Sulindac for polyposis of the colon. J Surg Oncol1983; 24:83–87.
18.
GiardielloFMHamiltonSRKrushAJ. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med1993; 28:1313–6.
19.
GiardielloFMOfferhausGJADuBoisRN. The role of non-steroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer1995; 31A:1071–6.
20.
WilliamsCSMannMDuBoisRN. The role of cyclooxygenases in inflammation, cancer and development. Oncogene1999; 18:7908–16.
21.
LimJTPiazzaGAHanEK. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol1999; 58:1097–107.
22.
WuGD. A nuclear receptor to prevent colon cancer. N Engl J Med2000; 342:651–3.
23.
MurrayLJAbramsTJLongKR. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis2003; 20:757–66.
24.
HoweLRDannenbergAJ. COX-2 Inhibitors in the prevention of breast cancer. Jou Mam Glan Bio Neo2003; 8:31–43.
25.
MitchellJAAkarasereenontPThiemermannCFlowerRJVaneJR. Selectivity of non-steroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA1994; 90:11693–7.
26.
KawamoriTWakabayashiK. COX-2 and prostanoid receptors: Good targets for chemoprevention. J Environ Pathol Toxicol Oncol2002; 21:149–53.
27.
MiliarasSMiliarasDVrettouEZavitsanakisAKiskinisD. The effect of aspirin and high fibre diet on colorectal carcinoma: A comparative experimental study. Tech Coloproctol2004; 8:59–61.
28.
DavisAEPattersonF. Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model. Aust N Z J Med1994; 24:301–3.
29.
PerseMZebicACerarA. Rofecoxib does not inhibit aberrant crypt foci formation but inhibits later steps in the development of experimental colorectal cancer: Rofecoxib in experimental colon cancer. Scand J Gastroenterol2005; 40:61–7.
30.
ThunMJHenleySJPatronoC. Non-steroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst2002; 94:252–66.
31.
HarrisREAlshafieGAAbou-IssaHSeibertK. Chemoprevention of Breast Cancer in Rats by Celecoxib, a Cyclooxygenase 2 Inhibitor. Cancer Res2000, 60:2101–03.
32.
MollLMvan EykADvan der BijlP. In vitro permeability of intact and de-epithelialised, human vaginal mucosa to Tacrolimus and Cyclosporin A. Eur J Inflamm2007; 5:7–13.
33.
AlshafieGAAbou-IssaHMSeibertKHarrisRE. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep2000; 7:1377–81.
34.
Lanza-JacobySMillerSFlynnJ. The Cyclooxygenase-2 Inhibitor, Celecoxib, prevents the development of mammary tumors in HER-2/neu mice. Cancer Epidemiol Biomarkers Prev2003; 12:1486–91.
35.
HugginsCGrandLCBrillantesFP. Mammary cancer induced by a single feeding of polynuclear hydrocarbons and its suppression. Nature1961; 189:204–7.
36.
DasRHossainSBhattacharyaS. Diphenylmethyl selenocyanate inhibits DMBA–croton oil induced two-stage mouse skin carcinogenesis by inducing apoptosis and inhibiting cutaneous cell proliferation. Cancer Letters2005; 230:90–101.
37.
DeepakPKumarSAcharyaA. IL-13 neutralization modulates function of type II polarized macrophages in vivo in a murine T-cell lymphoma. Eur J Inflamm2007; 5:37–45.
38.
AromandoRFPerezMAHeberEMTrivillinVATomasiVHSchwintAEItoizME. Potential role of mast cells in hamster cheek pouch carcinogenesis. Oral Oncol2008; 44:1080–7.
39.
OrcianiMTrubianiOCavalettiGGuarnieriSSalvoliniETrediciGDi PrimioR. Expression of CD38 in human neuroblastoma SH-SY5Y cells. Int J Immunopathol Pharmacol2008; 21:97–106.
40.
WalentinssonASjölingAHelouKKlinga-LevanKLevanG. Genomewide assessment of genetic alterations in DMBA-induced rat sarcomas: Cytogenetic, CGH, and allelotype analyses reveal recurrent DNA copy number changes in rat chromosomes 1, 2, 4, and 7. Genes Chromosomes Cancer2000; 28:184–95.
41.
KwonKi HanBarveAvantikaSiwangYuHuangMou-TuanKongAh-Ng Tony. Cancer chemoprevention by phytochemicals: Potential molecular targets, biomarkers and animal models. Acta Pharmacologica Sinica2007; 28:1409–21.
42.
CapodiferroSScullyCFicarraG. Orofacial granulomatosis: Report of two cases with gingival onset. Eur J Inflamm2007; 5:51–6.
43.
TalasZ SelamogluOzdemirIYilmazIGokYOrunI. The investigation of the antioxidative properties of the novel synthetic organoselenium compounds in the some rat tissues. Exp Biol Med (Maywood)2008; 233:575–9.
44.
GhoneumMMatsuuraMGollapudiS. Modified arabinoxylan rice bran (mgn-3/biobran) enhances intracellular killing of microbes by human phagocytic cells in vitro. Int J Immunopathol Pharmacol2008; 21:87–96.
45.
RuggeriBAKlurfeldDMKritchevskyDFurlanettoRW. Caloric restriction and 7,12-dimethylbenz(a)an thracene-induced mammary tumor growth in rats: Alterations in circulating insulin, insulin-like growth factors I and II, and epidermal growth factor. Cancer Res1989; 49:4130–4.
46.
MotoyamaJYamashitaNMorinoTTanakaMKobayashiTHondaH. Hyperthermic treatment of DMBA-induced rat mammary cancer using magnetic nanoparticles. Biomagn Res Technol2008; 25:6–12.
47.
ShimkinMBGruensteinMMeranzeDRAcuffMThatcherD. The effects of schedule and dose of 7,12-Dimethylbenz(a)-anthracene on the induction and growth of mammary carcinomas in Sprague-Dawley female rats. Cancer Res1969; 29:503–5.
48.
MorrisHP. Studies on the development, biochemistry, and biology of experimental hepatomas. Advan Cancer Res1965; 9:228–302.
49.
TellerMNStockCCStohrGMerkerPCKaufmanRJEscherGCBowieM. Biologic characteristics and chemotherapy of 7,12-Dimethylbenz(a)anthrac ene-induced tumors in rats. Cancer Res1966; 26: 245–52.
50.
LoscherWMevissenMHaulerM. Seasonal Influence on 7,12-dimethylbenz[a]anthracene-induced mammary carcinogenesis in Sprague-Dawley rats under controlled laboratory conditions. Pharmacol Toxicol1997; 81:265–70.
51.
GearRBYanMSchneiderJSuccopPHeffelfingerSCCleggDJ. Charles river sprague dawley rats lack early age-dependent susceptibility to DMBA-induced mammary carcinogenesisInt J Biol Sci2007; 3:408–416.
52.
LeeSYNgSFBusbyWFRogersAE. Mammary gland DNA synthesis in rats fed high lard or control diets. J Nutr Growth & Cancer1987; 4:167–74.
53.
LeeSYWalshCTNgSFRogersAE. Toxicokinetics of 7,12-Dimethylbenz(at)anthracene (DMBA) in rats fed high lard or control diets. J Nutri Growth & Cancer1986; 3:167–76.
54.
RogersAE. Factors that modulate chemical carcinogenesis in the mammary gland of the female rat, JonesT. C.MohrU.HuntR. D., eds. 1989 (Berlin, Heidelberg: Springer-Verlag).
55.
ThompsonHJJiangWZhuZ. Mechanisms by which energy restriction inhibits carcinogenesis. Adv Exp Med Biol1999; 470:77–84.
56.
MehtaRG. Experimental basis for the prevention of breast cancer. Eur J Cancer2000; 36:1275–82.
